You are here

Article info

Article menu

Download PDFPDF

Commentary
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy

Authors

  • Tomoko Akaike Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Austin J Jabbour Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Peter H Goff Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USARadiation Oncology Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USADivision of Radiation Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA PubMed articlesGoogle scholar articles
  • Song Y Park Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Shailender Bhatia Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USAFred Hutchinson Cancer Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Paul Nghiem Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USAFred Hutchinson Cancer Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles

Citation

Akaike T, Jabbour AJ, Goff PH, et al
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
Journal for ImmunoTherapy of Cancer 2024;12:e009396. doi: 10.1136/jitc-2024-009396
Online issue publication 
July 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.